4.6 Review

T cell response to SARS-CoV-2 infection in humans: A systematic review

期刊

PLOS ONE
卷 16, 期 1, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0245532

关键词

-

资金

  1. NIHR Doctoral Fellowship [NIHR300156]
  2. National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London
  3. Wellcome Trust Clinical Research Training Fellowship [215654/Z/19/Z]
  4. Wellcome Trust [215654/Z/19/Z] Funding Source: Wellcome Trust
  5. National Institutes of Health Research (NIHR) [NIHR300156] Funding Source: National Institutes of Health Research (NIHR)

向作者/读者索取更多资源

The study found that COVID-19 patients exhibit T cell lymphopenia, which is positively correlated with disease severity, duration of RNA positivity, and non-survival. Those with severe or critical disease tend to develop more robust, virus-specific T cell responses. Cross-reactive T cell responses have been demonstrated in unexposed and uninfected adults, but their significance for protection and susceptibility remains unclear.
Background Understanding the T cell response to SARS-CoV-2 is critical to vaccine development, epidemiological surveillance and disease control strategies. This systematic review critically evaluates and synthesises the relevant peer-reviewed and pre-print literature published from 01/01/2020-26/06/2020. Methods For this systematic review, keyword-structured literature searches were carried out in MEDLINE, Embase and COVID-19 Primer. Papers were independently screened by two researchers, with arbitration of disagreements by a third researcher. Data were independently extracted into a pre-designed Excel template and studies critically appraised using a modified version of the MetaQAT tool, with resolution of disagreements by consensus. Findings were narratively synthesised. Results 61 articles were included. 55 (90%) studies used observational designs, 50 (82%) involved hospitalised patients with higher acuity illness, and the majority had important limitations. Symptomatic adult COVID-19 cases consistently show peripheral T cell lymphopenia, which positively correlates with increased disease severity, duration of RNA positivity, and non-survival; while asymptomatic and paediatric cases display preserved counts. People with severe or critical disease generally develop more robust, virus-specific T cell responses. T cell memory and effector function has been demonstrated against multiple viral epitopes, and, cross-reactive T cell responses have been demonstrated in unexposed and uninfected adults, but the significance for protection and susceptibility, respectively, remains unclear. Conclusion A complex pattern of T cell response to SARS-CoV-2 infection has been demonstrated, but inferences regarding population level immunity are hampered by significant methodological limitations and heterogeneity between studies, as well as a striking lack of research in asymptomatic or pauci-symptomatic individuals. In contrast to antibody responses, population-level surveillance of the T cell response is unlikely to be feasible in the near term. Focused evaluation in specific sub-groups, including vaccine recipients, should be prioritised.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Public, Environmental & Occupational Health

Comparative effectiveness of different primary vaccination courses on mRNA-based booster vaccines against SARs-COV-2 infections: a time-varying cohort analysis using trial emulation in the Virus Watch community cohort

Vincent Grigori Nguyen, Alexei Yavlinsky, Sarah Beale, Susan Hoskins, Thomas E. Byrne, Vasileios Lampos, Isobel Braithwaite, Wing Lam Erica Fong, Ellen Fragaszy, Cyril Geismar, Jana Kovar, Annalan M. D. Navaratnam, Parth Patel, Madhumita Shrotri, Sophie Weber, Andrew C. Hayward, Robert W. Aldridge

Summary: The UK's booster vaccination program used mRNA vaccines to protect against the Omicron variant, regardless of the individual's primary vaccine type, and prioritized the clinically vulnerable. After mRNA booster vaccinations, there was no difference in protection between individuals who received the BNT162b2 primary vaccine and those who received the ChAdOx1 primary vaccine.

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2023)

Article Genetics & Heredity

Germline mismatch repair (MMR) gene analyses from English NHS regional molecular genomics laboratories 1996-2020: development of a national resource of patient-level genomics laboratory records

Lucy Loong, Catherine Huntley, Fiona McRonald, Francesco Santaniello, Joanna Pethick, Bethany Torr, Sophie Allen, Oliver Tulloch, Shilpi Goel, Brian Shand, Tameera Rahman, Margreet Luchtenborg, Alice Garrett, Richard Barber, Tin Bedenham, David Bourn, Kirsty Bradshaw, Claire Brooks, Jonathan Bruty, George J. Burghel, Samantha Butler, Chris Buxton, Alison Callaway, Jonathan Callaway, James Drummond, Miranda Durkie, Joanne Field, Lucy Jenkins, Terri P. McVeigh, Roger Mountford, Rodney Nyanhete, Evgenia Petrides, Rachel Robinson, Tracy Scott, Victoria Stinton, James Tellez, Andrew J. Wallace, Laura Yarram-Smith, Kate Sahan, Nina Hallowell, Diana M. Eccles, Paul Pharoah, Marc Tischkowitz, Antonis C. Antoniou, D. Gareth Evans, Fiona Lalloo, Gail Norbury, Eva Morris, John Burn, Steven Hardy, Clare Turnbull

Summary: This study describes the national patterns of NHS analysis of MMR genes in England using individual-level data submitted to NDRS by regional molecular genetics laboratories. The NDRS MMR dataset is a unique national amalgamation of clinical and genomic patient data, enabling data linkage to other national datasets. This resource can enable longitudinal research and form the basis of a live national genomic disease registry.

JOURNAL OF MEDICAL GENETICS (2023)

Article Immunology

Clinical Effectiveness of SARS-CoV-2 Booster Vaccine Against Omicron Infection in Residents and Staff of Long-term Care Facilities: A Prospective Cohort Study (VIVALDI)

Oliver Stirrup, Madhumita Shrotri, Natalie L. Adams, Maria Krutikov, Hadjer Nacer-Laidi, Borscha Azmi, Tom Palmer, Christopher Fuller, Aidan Irwin-Singer, Verity Baynton, Gokhan Tut, Paul Moss, Andrew Hayward, Andrew Copas, Laura Shallcross

Summary: This study investigated the effectiveness of booster vaccination against infections, hospitalizations, and deaths among LTCF residents and staff in England. The results showed that booster vaccination provided sustained protection against severe outcomes following infection with the Omicron variant, but no protection against infection from 4 months onwards.

OPEN FORUM INFECTIOUS DISEASES (2023)

Article Oncology

Utility of polygenic risk scores in UK cancer screening: a modelling analysis

Catherine Huntley, Bethany Torr, Amit Sud, Charlie F. Rowlands, Rosalind Way, Katie Snape, Helen Hanson, Charles Swanton, John Broggio, Anneke Lucassen, Margaret McCartney, Richard S. Houlston, Aroon D. Hingorani, Michael E. Jones, Clare Turnbull

Summary: It is proposed that polygenic risk scores (PRSs), by targeting high-risk individuals, can improve the efficiency of cancer screening programs and expand their application to new age groups and types of cancer. This study presents an overview of the performance of PRS tools and the benefits and harms of PRS-stratified cancer screening for eight example cancers.

LANCET ONCOLOGY (2023)

Article Immunology

Case report: Clearance of longstanding, immune-deficiency-associated, vaccine-derived polio virus infection following remdesivir therapy for chronic SARS-CoV-2 infection

William Hywel Bermingham, Benjamin Canning, Thomas Wilton, Michael Kidd, Dimitra Klapsa, Manasi Majumdar, Kavitha Sooriyakumar, Javier Martin, Aarnoud P. Huissoon

Summary: The global polio eradication campaign has effectively reduced wild-type poliovirus infections through the use of a live attenuated Sabin oral poliovirus vaccine. However, rare cases of vaccine-derived poliovirus (VDPV) infections may occur and pose challenges to eradication efforts, especially in immunocompromised individuals. This case study presents a patient with persistent VDPV infection, which was successfully treated with remdesivir, a drug commonly used for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. These findings support further exploration of remdesivir as a potential cure for iVDPV infections.

FRONTIERS IN IMMUNOLOGY (2023)

Article Oncology

Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study

Sophie Papa, Antonella Adami, Michael Metoudi, Richard Beatson, Molly Sarah George, Daniela Achkova, Evangelia Williams, Sefina Arif, Fiona Reid, Maria Elstad, Nicholas Beckley-Hoelscher, Abdel Douri, Marc Delord, Mike Lyne, Dharshene Shivapatham, Christopher Fisher, Andrew Hope, Sakina Gooljar, Arindam Mitra, Linda Gomm, Cienne Morton, Rhonda Henley-Smith, Selvam Thavaraj, Alice Santambrogio, Cynthia Andoniadou, Sarah Allen, Victoria Gibson, Gary J. R. Cook, Ana C. Parente-Pereira, David M. Davies, Farzin Farzaneh, Anna Schurich, Teresa Guerrero-Urbano, Jean-Pierre Jeannon, James Spicer, John Maher

Summary: This study developed an autologous CD28-based chimeric antigen receptor T-cell (CAR-T) therapy named T4 immunotherapy for locally advanced/recurrent head and neck squamous cell carcinoma (HNSCC). Patient-derived T-cells were engineered to express a panErbB-specific CAR and an IL-4-responsive chimeric cytokine receptor. Intratumoral delivery was used to mitigate off-tumor toxicity. The study demonstrated the safe and effective intratumoral administration of T4 immunotherapy in advanced HNSCC.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Review Oncology

CAR-Based Immunotherapy of Solid Tumours-A Survey of the Emerging Targets

John Maher, David M. Davies

Summary: A new approach to treating cancer involves re-programming patient immune cells to express a cancer-detecting receptor called a CAR. While this method has been successful in treating blood cancers, it is more challenging to treat solid tumors. The identification of targets that differentiate cancer cells from healthy cells is a major obstacle. In a review, clinical data on CAR-based immunotherapy against solid tumors expressing 30 different targets were analyzed, and additional candidates for future clinical evaluation were suggested based on pre-clinical data.

CANCERS (2023)

Review Biology

CAR Based Immunotherapy of Solid Tumours-A Clinically Based Review of Target Antigens

John Maher, David M. Davies

Summary: Cancer is a leading cause of death and new immune-based therapies show promise for addressing this problem. Using immune white blood cells with added genetic blueprints, known as CAR cells, has been effective in treating blood cancers. However, treating solid tumors, which account for 90% of all cancers, is more challenging. This review surveys the use of CAR cells in clinical trials and highlights the difficulties in identifying targets and ensuring safety.

BIOLOGY-BASEL (2023)

Article Public, Environmental & Occupational Health

Tracking Changes in Mobility Before and After the First SARS-CoV-2 Vaccination Using Global Positioning System Data in England and Wales (Virus Watch): Prospective Observational Community Cohort Study

Vincent Nguyen, Yunzhe Liu, Richard Mumford, Benjamin Flanagan, Parth Patel, Isobel Braithwaite, Madhumita Shrotri, Thomas Byrne, Sarah Beale, Anna Aryee, Wing Lam Erica Fong, Ellen Fragaszy, Cyril Geismar, Annalan M. D. Navaratnam, Pia Hardelid, Jana Kovar, Addy Pope, Tao Cheng, Andrew Hayward, Robert Aldridge

Summary: Evidence suggests that adherence to public health policies may change after individuals receive their first SARS-CoV-2 vaccine. This study analyzed the daily travel distance of participants before and after vaccination and found that there was a small change in movement after vaccination.

JMIR PUBLIC HEALTH AND SURVEILLANCE (2023)

Letter Infectious Diseases

Management of suspected hypersensitivity reactions to anti-TB drugs

L. Mutlu, W. H. Bermingham, O. E. Mohamed, C. Melchior, L. Samuel, J. Heslegrave, R. Baretto, A. Ekbote, A. Huissoon, M. Dedicoat, M. T. Krishna

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2023)

Review Biotechnology & Applied Microbiology

Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Lung Cancer: Current Perspectives

John Maher

Summary: Immunotherapy using CAR-engineered T-cells has shown great efficacy in hematological cancers but faces challenges in treating solid tumors like lung cancer. Obstacles include selecting safe tumor-specific targets and overcoming tumor heterogeneity. Additionally, CAR T-cells need to efficiently infiltrate tumor deposits and function in the hostile tumor microenvironment. Despite the adaptability of lung cancer, immune checkpoint blockade has shown promise in controlling advanced lung carcinomas. This review summarizes pre-clinical and ongoing clinical trials in CAR T-cell therapy for lung cancer and discusses strategies to improve efficacy.

ONCOTARGETS AND THERAPY (2023)

Review Biology

The Role and Regulation of the NKG2D/NKG2D Ligand System in Cancer

Ge Tan, Katelyn M. Spillane, John Maher

Summary: The human NKG2D ligand family consists of eight stress-induced molecules. These ligands are expressed by over 80% of human cancers, but can also have immunosuppressive effects due to shedding, release via exosomes, and intracellular trapping. NKG2D deficiency in mice increases susceptibility to some types of cancer, indicating its role in immune surveillance for malignancy.

BIOLOGY-BASEL (2023)

Article Cell Biology

Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes

Gokhan Tut, Tara Lancaster, Maria Krutikov, Panagiota Sylla, David Bone, Eliska Spalkova, Christopher Bentley, Umayr Amin, Azar Jadir, Samuel Hulme, Nayandeep Kaur, Elif Tut, Rachel Bruton, Mary Wu, Ruth Harvey, Edward J. Carr, Rupert Beale, Oliver Stirrup, Madhumita Shrotri, Borscha Azmi, Christopher Fuller, Verity Baynton, Aidan Irwin-Singer, Andrew Hayward, Andrew Copas, Laura Shallcross, Paul Moss

Summary: Older people have suboptimal responses to primary series vaccines, but booster vaccines can increase antibody levels in the short term. However, antibody levels decline within 100 days after the booster shots and breakthrough infections can still occur. This study highlights the strong immunogenicity of a third vaccine dose in vulnerable older populations and supports widespread vaccination in this group.

NATURE AGING (2023)

Article Pharmacology & Pharmacy

Harnessing Nanomedicine to Potentiate the Chemo-Immunotherapeutic Effects of Doxorubicin and Alendronate Co-Encapsulated in Pegylated Liposomes

Alberto Gabizon, Hilary Shmeeda, Benjamin Draper, Ana Parente-Pereira, John Maher, Amaia Carrascal-Minino, Rafael T. M. de Rosales, Ninh M. La-Beck

Summary: The co-encapsulation of alendronate and doxorubicin in pegylated liposomes (PLAD) has shown significant immune modulatory effects and distinct tumor microenvironmental interactions compared to free doxorubicin and the clinical formulation of pegylated liposomal doxorubicin.

PHARMACEUTICS (2023)

Article Geriatrics & Gerontology

Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study

Madhumita Shrotri, Maria Krutikov, Hadjer Nacer-Laidi, Borscha Azmi, Tom Palmer, Rebecca Giddings, Christopher Fuller, Aidan Irwin-Singer, Verity Baynton, Gokhan Tut, Paul Moss, Andrew Hayward, Andrew Copas, Laura Shallcross

Summary: Vaccination effectiveness against SARS-CoV-2 infection, hospitalisation, and death declined over time in residents and staff of long-term care facilities following initial doses, but was restored and maximised after a third vaccine dose. Boosters are crucial for maintaining protection in this vulnerable population.

LANCET HEALTHY LONGEVITY (2022)

暂无数据